Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
KDMF
0
NDC API
0
VMF
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Brexafemme
2. Ibrexafungerp
3. Mk-3118
4. Scy-078
1. Scy-078 Citrate
2. M4nu2sdx3e
3. Ibrexafungerp Citrate [usan]
4. 1965291-08-0
5. Ibrexafungerp Citrate (usan)
6. Brexafemme
7. Unii-m4nu2sdx3e
8. Chembl4298168
9. Glxc-26020
10. Ibrexafungerp Citrate [who-dd]
11. Ibrexafungerp Citrate [orange Book]
12. D11545
13. (1s,4ar,6as,7r,8r,10ar,10br,12ar,14r,15r)-15-((2r)- 2-amino-2,3,3-trimethylbutoxy)-1,6a,8,10a-tetramethyl-8- ((2r)-3-methylbutan-2-yl)-14-(5-(pyridin-4-yl)-1h-1,2,4- Triazol-1-yl)-1,6,6a,7,8,9,10,10a,10b,11,12,12a-dodecahydro-2h,4h-1,4a-propanophenanthro(1,2-c)pyran-7-carboxylic Acid Compound With 2-hydroxypropane-1,2,3-tricarboxylic Acid (1:1)
14. 4h-1,4a-propano-2h-phenanthro(1,2-c)pyran-7-carboxylic Acid, 15-((2r)-2-amino-2,3,3-trimethylbutoxy)-8-((1r)-1,2-dimethylpropyl)-1,6,6a,7,8,9,10,10a,10b,11,12,12a-dodecahydro-1,6a,8,10a-tetramethyl-14-(5-(4-pyridinyl)-1h-1,2,4-triazol-1-yl)-, (1s,4ar,6as
15. 4h-1,4a-propano-2h-phenanthro(1,2-c)pyran-7-carboxylic Acid, 15-((2r)-2-amino-2,3,3-trimethylbutoxy)-8-((1r)-1,2-dimethylpropyl)-1,6,6a,7,8,9,10,10a,10b,11,12,12a-dodecahydro-1,6a,8,10a-tetramethyl-14-(5-(4-pyridinyl)-1h-1,2,4-triazol-1-yl)-, (1s,4ar,6as,7r,8r,10ar,10br,12ar,14r,15r)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
Molecular Weight | 922.2 g/mol |
---|---|
Molecular Formula | C50H75N5O11 |
Hydrogen Bond Donor Count | 6 |
Hydrogen Bond Acceptor Count | 15 |
Rotatable Bond Count | 14 |
Exact Mass | 921.54630823 g/mol |
Monoisotopic Mass | 921.54630823 g/mol |
Topological Polar Surface Area | 258 Ų |
Heavy Atom Count | 66 |
Formal Charge | 0 |
Complexity | 1650 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 12 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Antifungal Agents
Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Date of Issue : 2022-06-08
Valid Till : 2025-06-16
Written Confirmation Number : WC-0037
Address of the Firm :
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Ibrexafungerp Citrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ibrexafungerp Citrate, including repackagers and relabelers. The FDA regulates Ibrexafungerp Citrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ibrexafungerp Citrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Ibrexafungerp Citrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Ibrexafungerp Citrate supplier is an individual or a company that provides Ibrexafungerp Citrate active pharmaceutical ingredient (API) or Ibrexafungerp Citrate finished formulations upon request. The Ibrexafungerp Citrate suppliers may include Ibrexafungerp Citrate API manufacturers, exporters, distributors and traders.
click here to find a list of Ibrexafungerp Citrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Ibrexafungerp Citrate written confirmation (Ibrexafungerp Citrate WC) is an official document issued by a regulatory agency to a Ibrexafungerp Citrate manufacturer, verifying that the manufacturing facility of a Ibrexafungerp Citrate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Ibrexafungerp Citrate APIs or Ibrexafungerp Citrate finished pharmaceutical products to another nation, regulatory agencies frequently require a Ibrexafungerp Citrate WC (written confirmation) as part of the regulatory process.
click here to find a list of Ibrexafungerp Citrate suppliers with Written Confirmation (WC) on PharmaCompass.
Ibrexafungerp Citrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ibrexafungerp Citrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ibrexafungerp Citrate GMP manufacturer or Ibrexafungerp Citrate GMP API supplier for your needs.
A Ibrexafungerp Citrate CoA (Certificate of Analysis) is a formal document that attests to Ibrexafungerp Citrate's compliance with Ibrexafungerp Citrate specifications and serves as a tool for batch-level quality control.
Ibrexafungerp Citrate CoA mostly includes findings from lab analyses of a specific batch. For each Ibrexafungerp Citrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ibrexafungerp Citrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Ibrexafungerp Citrate EP), Ibrexafungerp Citrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ibrexafungerp Citrate USP).
LOOKING FOR A SUPPLIER?